F. Graf Finckenstein
Fox Chase Cancer Center
6 Papers
F. Graf Finckenstein is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney,Karl D. Lewis,Harriet M. Kluger,Omid Hamid,Eric D. Whitman,Sajeve Samuel Thomas,Martin Wermke,Mike Cusnir,Evidio Domingo-Musibay,Giao Q. Phan,John M. Kirkwood,Jessica C. Hassel,Marlana Orloff,James Larkin,Jeffrey S. Weber,Andrew Furness,Nikhil I. Khushalani,Theresa Medina,Michael E. Egger,F. Graf Finckenstein,Madan Jagasia,Parameswaran Hari,Girija G. Sulur,Wen Shi,Xiao Wu,A.S. Sarnaik +25 more
TL;DR: In this paper , an independent review committee (IRC)-assessed outcome of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma was reported.
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Adam J. Schoenfeld,Sylvia M. Lee,Bernard Doger de Speville,S. Gettinger,Simon Hafliger,Ammar Sukari,Sophie Papa,Juan Francisco Rodriguez-Moreno,F. Graf Finckenstein,Rana Fiaz,Melissa Catlett,Guang Chen,Rongsu Qi,Emma L Masteller,Viktoria Gontcharova,Kai He +15 more
TL;DR: Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy and is evaluated as a potential treatment option for patients with mNSCLC refractory to prior therapy.
15
883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Jason Chesney,Trisha Wise-Draper,Amod A. Sarnaik,F. Graf Finckenstein,Parameswaran Hari,Madan Jagasia,A. Desai,A. Suzuki,X Wu,Allison Betof Warner +9 more
TL;DR: IOV-4001 as mentioned in this paper is a TALEN-mediated PDCD-1 knockout autologous TIL cell therapy product, which has demonstrated efficacy in patients (pts) with advanced solid tumors, including melanoma.
6
EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC
Jason Chesney,Adam J. Schoenfeld,Trisha Wise-Draper,Ammar Sukari,Kewu He,F. Graf Finckenstein,Parameswaran Hari,Madan Jagasia,Selda Samakoglu,A. Leighton-Swayze,G. Chen,Yong-Kil Hong +11 more
TL;DR: Schoenfeld et al. as mentioned in this paper proposed LN-145, an autologous TIL cell therapy, which demonstrated feasibility, safety, and an early signal of efficacy with a 21.4% objective response rate (ORR) in heavily pretreated patients with mNSCLC, including responders with PD-L1-negative tumors.